Abstract
Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/μL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.
Original language | English (US) |
---|---|
Pages (from-to) | 120-124 |
Number of pages | 5 |
Journal | American Journal of Kidney Diseases |
Volume | 11 |
Issue number | 2 |
DOIs | |
State | Published - 1988 |
Keywords
- MoAb
- OKT3
- human antimurine response
- immunoglobulin idiotypes
- monoclonal antibody
- retreatment
ASJC Scopus subject areas
- Nephrology